Although genetic and physiopathological aspects of SDHD mutations have been deeply studied, current pheochromocytomas and PGLs clinical guidelines [6] do not focus specifically on the clinical management of FPGL1 patients. The gene discussed is SDHD; the disease is hereditary pheochromocytoma-paraganglioma.